International Stem Cell ISCO
OTC ISCO
$0.14 -0.01 (-6.67%)
At close: Oct 23, 2026 · 4:00 PM EDT

International Stem Cell (ISCO) Gains from Sales and Divestitures (2011 - 2018)

Updated

International Stem Cell (ISCO) reported Gains from Sales and Divestitures of -$24,000 for Q4 2018.

Analysis

International Stem Cell (ISCO) Gains from Sales and Divestitures (2011 - 2018) Analysis & Trends

For FY2018, International Stem Cell posted Gains from Sales and Divestitures of -$25,000.

  • By year, Gains from Sales and Divestitures came in at -$1,000 in FY2015 and -$9,000 in FY2014.
  • The Q4 2018 figure ranks as the lowest quarterly Gains from Sales and Divestitures since Q4 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 International Stem Cell 1.12 Mn -2.85 Mn 1.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -24,000.00
Mar 31, 2018 -1,000.00
Dec 31, 2014 -1,000.00
Dec 31, 2013 -52,000.00
Dec 31, 2012 -6,000.00
Dec 31, 2011 -15,000.00
API Access

International Stem Cell Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ISCO&period=max&api_key=YOUR_API_KEY